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Abstract: Anti-microbial resistance is a growing problem that has impacted the world and brought
about the beginning of the end for the old generation of antibiotics. Increasingly, more antibiotics are
being prescribed unnecessarily and this reckless practice has resulted in increased resistance towards
these drugs, rendering them useless against infection. Nanotechnology presents a potential answer to
anti-microbial resistance, which could stimulate innovation and create a new generation of antibiotic
treatments for future medicines. Preserving existing antibiotic activity through novel formulation
into or onto nanotechnologies can increase clinical longevity of action against infection. Additionally,
the unique physiochemical properties of nanoparticles can provide new anti-bacterial modes of action
which can also be explored. Simply concentrating on antibiotic prescribing habits will not resolve
the issue but rather mitigate it. Thus, new scientific approaches through the development of novel
antibiotics and formulations is required in order to employ a new generation of therapies to combat
anti-microbial resistance.
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1. Introduction
Anti-microbial resistance is a global problem that is affecting modern healthcare. Due to
inappropriate habits in the prescribing of antibiotics, anti-microbial resistance to an array of
different classes of antibiotics has occurred [1]. This phenomenon will undoubtedly significantly
impact the future efficacy and usage of antibiotics within both community and hospital care
globally [2,3]. In February 2017, the World Health Organisation (WHO) published its first-ever
list of antibiotic-resistant pathogens for which new anti-microbials are needed urgently [4]. Out of
the 12 resistant pathogens listed, seven were noted to possess resistance to beta-lactam antibiotics.
The three pathogens categorised as “Critical” are resistant to carbapenems, imipenem for example,
and four others are resistant to fluoroquinolones, such as ciprofloxacin (Figure 1) which are also
widely used in clinical practice. This is an alarming fact as in the future this will not only challenge
prescribing practices but will also increase the difficulty in obtaining suitable antibiotics to treat patients.
Nevertheless, the WHO has commented that this is an opportunity for the research and development
(R & D) sector to produce novel antibiotics, setting a new goal for future research strategies.
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Figure 1. Chemical structure of (A) imipenem and (B) ciprofloxacin.
Bacteria are prokaryotes, they do not possess a nuclear membrane and are classified as being
Gram-positive or Gram-negative, based broadly upon the structure of their cell wall (Figure 2). Gram’s
stain experiment classifies bacteria according to the ability of the bacterial cell wall to absorb and
retain crystal violet dye: Gram-positive bacteria retain the stain whereas Gram-negative bacteria do
not [5]. Gram-positive bacteria possess a rigid cell wall comprising a thick layer of peptidoglycan,
which is composed of carbohydrate polymers cross-linked through peptide residues [6]. Teichoic
acid is found on the surface of Gram-positive bacteria, which confers the ability to chelate metal ions
and act as a protection mechanism against the host immune response [7]. Lipoteichoic acids are also
present in the cell membrane, which allow surface adherence [8]. Conversely, Gram-negative bacteria
contain a thinner, more rigid peptidoglycan layer with much shorter cross-links, surrounded by a
lipid membrane with lipopolysaccharides (LPS) presented on the surface [9]. Staphylococcus aureus is
an example of a Gram-positive bacterium: Methicillin resistant S. aureus (MRSA) [10] is commonly
recognised by the lay person as being associated with antibiotic resistance. MRSA infections require
prolonged treatment regimens, often with powerful antibiotics and are consequently responsible for
elevated levels of patient hospitalisation and public spending. Klebsiella pneumoniae is a Gram-negative
bacterium that is present normally in the gastrointestinal tract, along with other species of bacteria, but
is associated with pneumonia, urinary tract and wound infections, bacteremia and septicaemia [11].
Likemany examples of Enterobacteriaceae, K. pneumoniae has developed resistance to carbapenems [12].
Mycobacteria present an additional threat: Mycobacteria have a unique, hydrophobic cell wall structure
and latent asymptomatic infections are common. A restricted number of antibiotics are reserved for
treatment ofMycobacterium tuberculosis infection (TB) but resistance to these is on the increase. TB was
declared a “global emergency” by the WHO [13], extensively drug-resistant TB (XDR-TB) is now rife
and totally drug-resistant strains ofM. tuberculosis have been observed [14].
The majority of common antibiotics discovered in the 20th century during the “golden age” are
derived from natural products. Antibiotics can be classified by their target, their molecular structure
and mode of action. For example, the principal targets for antibiotics in bacteria are assembly of the
cell wall, protein synthesis and the synthesis of nucleic acids. Classes of antibiotics which inhibit
the synthesis of peptidoglycan include the beta-lactams and glycopeptides; these two classes have
different modes of action so their use does not confer cross-resistance, though the glycopeptides are
only of use to treat Gram-positive infections. Major classes of antibiotics that target protein synthesis
include the macrolides and aminoglycosides. Synthesis and replication of DNA is inhibited by the
fluoroquinolones [15]. Other antibiotics, such as the lipopeptides and polymixins can disrupt the cell
walls of bacteria: colistin, a polymixin, is often cited as the drug of last resort yet resistance to colistin
has been observed [16]. Significantly, none of the classes of antibiotics used clinically incorporate metal
atoms in their structure.
The over-use of potent antibiotics such as vancomycin, a glycopeptide that inhibits the formation
of cross-links in the assembly of peptidoglycan, to treat infections by pathogenic Gram-positive bacteria
which are resistant to beta-lactams has led to a greater occurrence of resistance to glycopeptides in these
species [17]. This further depletes the pool of last line antibiotics that are useful clinically. Intrinsic
resistance mechanisms exhibited by bacteria and coded for in the genome, examples of which include a
lack of oxidative metabolismwhich prevents drug uptake or the presence of an outer lipid membrane in
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the Gram-negative bacteria cell wall which prevents uptake of glycopeptides, present other challenges.
Resistance to antibiotics can be acquired [18,19] by horizontal gene transfer whereby antibiotic-resistant
bacteria donate DNA, typically integrated into a plasmid and codes for that resistance mechanism,
to previously susceptible bacteria. This DNA is retained in the recipient cell, within a plasmid or is
transposed into the genome, and expression results in organisms that now harbour resistance to the
given antibiotic. This may include the acquisition of code for the production of beta-lactamases that
are responsible for enzymic degradation of beta-lactam antibiotics [20], or the transfer of transposable
elements such as the transposon Tn1546 which confers VanA type resistance to vancomycin in the
Enterococci and in S. aureus [21], for example.
Figure 2. Common antibiotic classes and their targets.
Today, with nanotechnology being more prevalent and applied in medicine it is not surprising to
see nanoparticle technologies being utilised in the fight against antibiotic resistance. Nanoparticles can
be utilised by (1) amalgamation with existing clinically relevant antibiotics to adapt and enhance their
physiochemical properties to overcome anti-microbial resistance mechanisms, or (2) as anti-microbial
agents in themselves, the colloidal forms of silver, zinc, copper, titanium and vanadium for example.
As noted above, the three principal targets for antibiotic action are inhibition of synthesis or disruption
of the cell wall, translation and transcription during protein synthesis and the synthesis of nucleic
acids. However, nanoparticle technologies have been found to affect the bacterial respiration system,
inducing generation of reactive oxygen species (ROS) in bacteria via compromising the bacterial
antioxidant system. This presents a new therapeutic approach to overcome anti-microbial resistance.
Silver nanoparticles, for example, target the bacterial cell wall [22], so by coupling clinically relevant
antibiotics onto the surface of these colloids the anti-bacterial activity of the drugs will be enhanced
through synergy. In this review, we will report the current development of nanoparticle technology for
combatting anti-microbial resistance.
2. Challenges to the Development of New Anti-Microbials
Despite the persistent growth in the occurrence of resistance to anti-microbial agents within
bacteria, there is a paucity of new antibiotics entering the market. This is possibly due to the reduced
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return on investment from such R&D activity, with the prospect of each new antibiotic having a limited
market after resistance to that drug has arisen. It has been proposed that an investment of $1.2 billion
USD into R & D is required to conduct the extensive research required to deliver a small portfolio of
new commercial entities [23]. Alternatively, it is more beneficial financially to develop and market
analogues of existing therapies rather than invest in new research [24]. Additionally, international
regulatory barriers have affected approval requirements, whereby a compoundmust exhibit superiority
instead of non-inferiority [25] to conventional therapies. Post-marketing pharmacovigilance of adverse
events may also jeopardise any potential candidates or therapies and, hence, the sector has not
prioritised research into novel antibiotics. This places the future of antibiotic drug discovery in
jeopardy: We are experiencing the situation in which some agencies demand development of a
new antibiotic arsenal, while at the same time other agencies inhibit such development, resulting
in stalemate. The pharmaceutical industry plays a vital role in driving R & D into new antibiotics.
Currently, there are few companies that invest significant resources in research and development
of antibiotics, with many others concentrating on developing generics as there is low risk in not
gaining return on investment compared to developing novel compounds [26]. Equally, most big
pharmaceutical companies have prioritised investment into drugs associated with chronic diseases that
require prolonged therapies [1]. In bacterial infection, therapy is mostly acute and, hence, development
of novel therapies has not drawn much attention when compared with other markets, such as oncology
where patient prognosis over a longer timeframe has demanded new therapies and overshadowed
the growing anti-microbial resistance epidemic. Interestingly, 50% of all antibiotics developed in “the
golden age” are still used clinically, with few new classes of antibiotics being developed in the 21st
Century [27]. Those novel antibiotics coming through the pipeline are typically analogues of previous
generations of antibiotics, which retain the samemechanism of action. Examples of antibiotics currently
emerging from the pipeline are gepotidacin (GSK2140944), a type 2 topoisomerase inhibitor with a
mode of action which differs from the commonly prescribed fluoroquinolones [28], and GSK3342830
which is a cephalosporin with activity against Gram-negative infections [29].
3. Challenges to the Strategies Employed to Develop New Anti-Microbials
Since the discovery of the naturally occurring penicillin in 1928 by Alexander Fleming,
modification of the core penicillin molecular structure by altering the properties of the side chain to give
semi-synthetic penicillins has been the major strategy employed to develop new beta-lactam antibiotics
from the penicillin family [30]. Besides the penicillins, development of other classes of antibiotics from
naturally occurring compounds has adopted the same strategy. Research using modern medicinal
chemistry paradigms has had limited success in developing novel, synthetic anti-microbial agents
that have novel modes of action to exert their anti-microbial properties. For example, development
of the oxazolidinone class of antibiotics, linezolid for example (Figure 3), in the latter decades of the
20th Century represents a recent example of a novel antibiotic class with a unique mechanism of
action. However, in common with the other classes of antibiotics available clinically, a similar fate
has befallen the oxazolidinones in that there is an increase in treatment failure due to the incidence
of bacterial resistance to the oxazolidinones. The controlled use of more established classifications of
antibiotics is often used as a strategy to combat resistance in bacteria [31]. However, a problem that is
faced when using some established classes of antibiotics is their toxicity: As examples, a significant
number of patients are allergic to penicillin, fluoroquinolones must not be used in children or elderly
patients due to the risk of musculoskeletal damage and tendinopathy, and dose-related progressive
ototoxicity is a risk when prescribing aminoglycosides. Nevertheless, there are potential opportunities
to develop novel nanoparticle formulations to increase the efficacy of established classes of antibiotics,
thus enabling dose reduction and limiting the associated toxicity.
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Figure 3. Chemical structure of linezolid.
4. Nanotechnology in Biomedicine
Nanotechnology is used widely in today’s biomedicine, with applications in drug delivery. It is
estimated that 60% of all drug entities under development are practically insoluble: solubility is
a major challenge in achieving desired bioavailability and appropriate levels of drug efficacy [32].
Nanotechnologies have been developed which not only improve drug solubility via encapsulation
but also promote enhanced permeation of membranes, longer circulation times and greater overall
efficiency. As knowledge has grown in this field and a multidisciplinary approach employed, targeted
therapeutics have been developed which allow the drug of choice to reach the desired site of action
in the body, thus allowing many toxic, insoluble and non-permeable drugs to enter clinical trial as
potential therapies [33].
5. Nanoparticles as Anti-Microbial Agents
5.1. Synergistic Application of Nanoparticles with Antibiotics
The conventional chemotherapeutic method of fighting infections with small-molecule antibiotic
drugs has led to the current, significant challenge of resistant bacteria. A particular problem is
the evolution of bacteria that are resistant to many antibiotic classes, so-called multidrug-resistant
(MDR) bacteria. As the number of useful first line antibiotics diminishes and last line drugs are
increasingly used to combat resistant infections, the number of treatment options for patients reduces.
Reserving the use of last line antibiotics will only delay the inevitable evolution of resistance to these
antibiotics. Conjugation of small molecule antibiotic drugs onto nanoparticles, silver nanoparticles
for example, is a possible approach to overcome the challenge of bacterial resistance by exploiting
the synergistic effect observed in the use of both the drug and the nanoparticle together. Shahverdi
and colleagues demonstrated elevated antibiotic activity against a panel of bacteria which included
S. aureus and Escherichia coli, using a combination treatment of silver nanoparticles with established
antibiotics [34]. Studies using colloidal silver conjugated with widely used antibiotics, such as
amoxicillin, erythromycin and vancomycin, itself only active against Gram-positive bacteria, (Figure 4)
have shown enhanced anti-bacterial activity [34]. Furthermore, Deng and colleagues showed that
a combination of tetracycline (Figure 4) bound to the surface of silver nanoparticles resulted in
elevated anti-bacterial action against Salmonella typhimurium relative to silver nanoparticles alone [35].
The tetracycline-silver nanoparticle complex enabled increased drug action due to greater silver
accumulation around the cell and, hence, this enhanced contact with the bacterial cell wall resulted
in increased bacterial growth inhibition. Similarly, Banoee and colleagues demonstrated an increase
in synergistic anti-bacterial activity using zinc oxide and ciprofloxacin (Figure 1) against E. coli and
S. aureus [36]. Despite achieving synergistic activity with ciprofloxacin, it was noted that combination
treatment of zinc oxide nanoparticles with amoxicillin and with nitrofurantoin (Figure 4) in fact
decreased the anti-bacterial activity against E. coli and S. aureus. Consequently, this study demonstrates
that combination treatment using nanoparticles combined with any antibiotic does not always result in
increased anti-microbial activity and that this may be drug- and nanoparticle-dependant [36]. Despite
that observation, these findings show potential for increasing the effectiveness and longevity of these
traditional antibiotics.
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Figure 4. Chemical structures of (A) amoxicillin; (B) erythromycin; (C) vancomycin; (D) tetracycline
and (E) nitrofurantoin.
5.2. Intrinsic Properties of Nanoparticles Which Confer Activity Against Bacteria
5.2.1. Generation of Reactive Oxidative Species
Reactive oxygen species (ROS) are formed in bacteria from aerobic respiration. Additionally,
free radicals can be generated via exposure to UV irradiation [37]. Derivatives generated by aerobic
respiratory metabolism, such as hydrogen peroxide, superoxide, and hydroxyl radicals are very
harmful and can lead to oxidative stress, which in turn causes damage to nucleotides and lipids in the
prokaryote cell [38]. By considering the function of ROS in bacterial respiration, these derivatives can
be used to cause bacterial mortality by compromising the cell’s antioxidant defence system. Superoxide
dismutase is responsible for bacterial defence against ROS by forming oxygen and hydrogen peroxide
by fusion of two superoxide anions [39]. Hence, oxidative stress can be induced by generating ROS via
the Fenton reaction, represented in Figure 5. This is achieved by introduction of a divalent metal ion
that will react with hydrogen peroxide to produce hydroxyl radicals which are capable of damaging
bacterial DNA and lipids [40].
 
Figure 5. Fenton reaction with Fe in its divalent form.
Li and colleagues reported anti-bacterial properties of zinc oxide and titanium oxide nanoparticles
after UV irradiation. Both nanoparticles generated superoxide, hydroxyl and singlet oxygen radicals
that induce oxidative stress and which resulted in anti-microbial activity [41]. Similarly, Reddy
and colleagues found that zinc nanoparticles have anti-bacterial activity via ROS action, initiated
by reducing the catalase enzyme synthesis which protects the bacteria form oxidative stress [42].
Furthermore, Dwivedi and colleagues reported the use of zinc nanoparticles which can interact with
Pseudomonas aeruginosa to generate ROS [43]. They showed that zinc nanoparticles first interact
with the outer membrane of the P. aeruginosa cell, after which the nanoparticles enter the cell and
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subsequently cause bacterial damage. The authors hypothesized that intracellular damage was
due to ROS production after inhibition of the respiratory enzymes which led to the increase in ROS
formation [43]. This hypothesis could be confirmed by inhibition of superoxide dismutase as previously
reported by Birben [39] and inhibition of catalase enzyme in the case of Reddy and colleagues [42].
Chatterjee and colleagues reported the anti-microbial activity of copper nanoparticles on E. coli
caused by lipid peroxidation [44]: Oxidative degradation of polyunsaturated lipids in the bacterial
membrane by peroxidation resulted in bacterial cell death by augmenting bacterial homeostasis.
Disruption to the membrane was also observed when the bacteria were incubated with copper
nanoparticles. Similarly, Padmavathy reported the use of zinc oxide nanoparticles capable of ROS
generation, resulting in damage to bacterial DNA and cellular proteins [45]. Additionally, these
nanoparticles were shown to infringe the bacterial lipid layer of the cell wall that resulted in damage
to its structure. By compromising the bacterial lipid layer this leads to exposure of intracellular
components of the bacteria that are vital for its homeostasis and proliferation. Thus, by damaging the
cell wall this leads to disrupted intracellular homeostasis and compromised bacterial function which
causes mortality.
Table 1 shows examples of nanoparticles which possess intrinsic anti-microbial properties across
a range of species of bacteria.
Table 1. Examples of nanoparticles exhibiting anti-bacterial properties and their mechanism of action.
Bacterial Species Gram Stain of theSpecies
Nanoparticle(s) with
Anti-Microbial Activity Mechanism of Action Reference
Staphylococcus aureus Gram-positive Ag Cell wall damage [46]
Campylobacter jejuni Gram-negative ZnO Growth inhibition by ROS [47]
Escherichia coli Gram-negative CuIONPs
Growth inhibition by ROS
ROS generation [48,49]
Pseudomonas aeruginosa Gram-negative AgZn
Enzyme inhibition in
respiratory chain complex
ROS generation
[43,50]
Klebsiella pneumoniae Gram-negative ZnO Growth inhibition [42]
Bacillus subtilis Gram-positive AgIONPs
DNA degradation
ROS generation [49,51]
5.2.2. Effects of Nanoparticles on Bacterial DNA and Metabolism
Gold nanoparticles were found to exert anti-bacterial activity by affecting prokaryote protein
synthesis. Ribosomal tRNA is involved in protein synthesis where it delivers amino acids for
translation, in order to synthesize new proteins [52]. Shamaila and colleagues showed that colloidal
gold affected protein synthesis by reducing the affinity of the ribosome for tRNA [53]. Furthermore,
they showed that the gold hindered bacterial metabolism by decreasing the activity of adenosine
triphosphate (ATP) synthase, the enzyme responsible for the formation of ATP from the reaction
of inorganic phosphate and ADP [53]. Moreover, the gold was also observed to affect the bacterial
respiratory chain by attacking nicotinamide adenine dinucleotide (NADH) dehydrogenase [53]. Here,
the gold nanoparticles were found to be irreversibly bound onto the thiol groups present on NADH
dehydrogenase, thus affecting the reduction-oxidation balance within the cell which results in the
generation of oxidative stress.
5.3. Effect of Nanoparticles on Inhibition of Biofilm Formation and Associated Infections
The presence of biofilm is often associated with chronic infections [54] that may have transferred
from surfaces, such as contaminated medical equipment and consequently presents problems
predominantly in hospitals and other healthcare settings [55]. Biofilm is a robust coating consisting
of a collection of bacterial communities which have adhered onto dense surfaces [56]. The biofilm
provides an additional resilient barrier against antibiotic treatment for the bacteria which explains
why infections caused by biofilm are more difficult to treat and may take longer to present [57,58].
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This resilience on abiotic surfaces means the microorganisms have a greater opportunity to spread
within a nosocomial setting which is an issue in hospitals especially, as the bacterial infection can be
transmitted more easily between patients from medical equipment. Antibiotics used prophylactically
during surgery normally decrease the probability of infection. However, since small doses are given
to patients for prophylaxis this increases the chance of developing a resistant infection, especially
dangerous if this resistance is present in colonies that have adhered to implants. If a biofilm has
entered the host this enables the bacteria to evade the host’s immune system which then leads to
chronic infection.
Chitosan is a biopolymer which was found to possess anti-bacterial activity when iron oxide
nanoparticles were incorporated into its structure. Iron oxide nanoparticles themselves are known
to possess intrinsic anti-microbial activity. The mechanism of this activity is the production of ROS
by the Fenton reaction, from free radicals produced during oxidation of the iron [59]. Chávez de Paz
and colleagues also demonstrated inhibition of biofilm formation and anti-microbial action arising
from a chitosan composite [60]. Shi and colleagues reported biofilm inhibition in the presence of
chitosan-coated iron oxide nanoparticles in an S. aureus model [61]. The proposed explanation for
chitosan-coated iron oxide nanoparticles modality was explained by Shrifian-Esfahni [62], whereby
positively charged amino groups of chitosan associate with negatively charged modules in the bacterial
cell wall, such as N-acetyl-muramic acid and sialic acid [62]. By this electrostatic interaction, chitosan
possibly limits bacterial growth via enzyme inhibition and metal chelation.
Titanium dioxide nanoparticles have also been found to inhibit biofilm formation. Jesline
and colleagues demonstrated inhibition of a MRSA biofilm in the presence of titanium oxide [63].
Application of titanium dioxide as an anti-bacterial agent has good potential since it is approved
for use already in medicines and cosmetics, for example. Furthermore, in addition to exhibiting
anti-bacterial efficacy in resistant bacteria it is also possible to conjugate antibiotics onto the surface
of titanium dioxide nanoparticles to assess whether there us any dual or synergistic anti-bacterial
action. Roy and colleagues demonstrated anti-bacterial activity of titanium dioxide nanoparticles
conjugated with different classes of antibiotics [64]. They showed elevated anti-bacterial activity as
observed by an increase in the zone of inhibition against MRSA which was treated with nanoparticles
conjugated to an individual antibiotic from the range investigated. The authors concluded that the
effectiveness of the antibiotics used was increased when treating MRSA in the presence of titanium
dioxide nanoparticles. However, the action responsible for such improved anti-bacterial activity still
needs to be studied [64]. Titanium nanoparticles were also found to be beneficial against MRSA in
bone implants. Calcium-Titanium Ca-Ti nanoparticles have been reported to elevate anti-bacterial
activity against MRSA infections in rabbits. Cao and colleagues proposed that calcium nanoparticles
were responsible for generating ROS from the reaction of calcium with water, producing hydroxyl
species which were then responsible for bacterial damage [65].
5.4. Physiochemical Properties of Nanoparticles Which Influence Anti-Microbial Activity
5.4.1. Size
Nanoparticle size is key in the interaction with bacterial surfaces as it will dictate the quantity of
nanoparticles capable of covering the cell surface, or the degree to which nanoparticles will penetrate
the bacterial cell wall. These parameters have a direct correlation to the extent of anti-bacterial activity
achieved. The mechanism of action of the nanoparticles, in terms of adhering to the cell wall structures
or intracellular internalisation is also dependant on the nanoparticle type. Nanoparticles up to 50 nm
diameter possess the ability to penetrate beyond the bacterial cell wall and can target the DNA
inside. Morones and colleagues reported the use of silver nanoparticles with a diameter of 10 nm [66]:
The particles possessed the ability to penetrate the bacteria and thus result in anti-microbial action [66].
Moreover, anti-microbial activity of silver nanoparticles against Bacillus subtilis was reported by Hsueh
and colleagues [51], whereby silver nanoparticles with a 10 nm diameter halted B. subtilis growth.
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Besides the size of the nanoparticle, it was not known whether the nanoparticle morphology was also
important for efficacy. Sadeghi and colleagues reported the use of silver nanoparticles of different
morphologies against E. coli and S. aureus [67]. They found that regardless of the shape of silver
nanoparticles, anti-microbial activity was achieved. Thus, this indicates that nanoparticle morphology
may not play a significant role in anti-microbial activity [67].
5.4.2. Zeta Potential
Zeta potential has been observed to play an important role in anti-bacterial activity of
nanoparticles. Zeta potential is an important property which contributes to an understanding
of the interaction of nanoparticles with bacterial cell surfaces [68]. The zeta potential will
determine the potential for nanoparticles to be exploited as drug carriers and also how augmenting
bacterial permeability can affect anti-microbial action. Moreover, the zeta potential can dictate the
pharmacokinetic behaviour of nanoparticles, especially important due to various pH changes within
the body that can affect the charge of the nanoparticle. The zeta potential is especially important in
dictating the stability of colloidal nanoparticle formulations. With respect to bacteria, zeta potential
can determine how much repulsion or association there will be between the nanoparticle and the
bacterial cell surface [69]. Zeta potential values are represented in mV, with zeta potential values
within the±30 mV range usually indicating moderate stability [70]. Gram-positive and Gram-negative
bacteria display different components on their cell surface, such as teichoic acid on Gram-positive
bacteria [7] and lipopolysaccharides (LPS) on Gram-negative bacteria [9]. The presence of these
surface components will affect the electrostatic properties of the associated nanoparticles and their
stability. LPS covers most of the cell surface in Gram-negative bacteria which causes the cell surface
to be negatively charged, thus it provides an opportunity for nanoparticles to target these cells
by exploiting electrostatic interaction. This negative surface charge possessed by Gram-negative
bacteria could explain why nanoparticles aggregate on the surface rather than penetrating the
prokaryote cell [71]. Snyder andMcIntosh proposed that LPS provides a selective barrier by preventing
hydrophilic molecules to penetrate the outer surface membrane [72]. In antibiotic-susceptible bacteria
lipid soluble antibiotics such as aminoglycosides can easily permeate through the outer membrane.
However, in MDR phenotypes the permeability of the bacterial cell wall is altered, such that it
prevents hydrophobic antibiotics to enter [73]. Moreover, in Gram-negative bacteria additional
pathways exist that can uptake hydrophilic molecules via general diffusion through porins by which
water-soluble antibiotics enter [73]. Hence, there is an opportunity for nanoparticles to use this pathway.
Since the Gram-negative bacterial cell surface is mostly negatively charged [74] this will dictate how
nanoparticles will interact. Many metal nanoparticles are cationic thus, due to such opposite charges
the zeta potential of nanoparticles will be vital to the degree to which nanoparticles will be bound
to the bacterial cell wall [75]. Halder and colleagues measured the zeta potentials of both S. aureus
and E. coli and found the zeta potential values for their surface charge to be  35.6 mV and  44.2mV,
respectively [69].
5.5. Nanoparticles as Drug Carriers
The clinical use of conventional antibiotics sometimes requires multiple doses to maintain
therapeutic plasma concentrations [76]. Hence, the problem of developing unwanted side effects
is increased, especially in elderly patients with impaired renal function which leads to elevated toxicity
profiles in the case of potent antibiotics [77]. Furthermore, the problematic physicochemical properties,
bioavailability and stability of certain antibiotics can result in the poor therapeutic performance of such
antibiotics and may eliminate antibiotic activity altogether. Thus, since the bacteria will be exposed to
continual environmental pressure of low concentrations of antibiotics this may potentiate the risk of
rising anti-microbial resistance. Conjugating drug molecules onto the surface of nanoparticles can help
improve these shortcomings. Hence, numerous studies have emerged reflecting this phenomenon,
predominantly using metallic nanoparticles as drug carriers resulting in increased anti-microbial effect.
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Saha and colleagues conjugated the three different antibiotics ampicillin, kanamycin and streptomycin
(Figure 6) onto the surface of colloidal gold [78]. Gold nanoparticles with ampicillin conjugated onto
their surface were found to have lower bactericidal activity than gold nanoparticles conjugated with
either kanamycin or streptomycin. The authors concluded that the exact reason for this difference
in activity profile is not known. However, they hypothesized that the differing bactericidal activity
was perhaps due principally to the mechanism of action of the specific antibiotics with the gold
nanoparticles attenuating this activity: ampicillin inhibits cell wall formation, whilst kanamycin and
streptomycin both inhibit the synthesis of proteins in prokaryotes [78].
Figure 6. Chemical structures of (A) ampicillin; (B) kanamycin and (C) streptomycin.
Brown and colleagues reported the functionalisation of both silver and gold nanoparticles with
ampicillin (Figure 6) [79]. They tested the nanoparticles alone as well as the formulated versions against
Gram-positive and Gram-negative bacteria. The data showed that the gold nanoparticles only exhibited
anti-microbial properties when the ampicillin was bound to the nanoparticle surface, whereas the
silver nanoparticles possessed some intrinsic anti-microbial properties, in agreement with other studies
presented in the literature. Following conjugation, the novel formulations exhibited a potent effect
on a broad range of bacterial species. Importantly, Brown’s study showed that both nanoparticulate
formulations exhibited unique properties, which avoided the mechanisms deployed by bacteria that
commonly result in the rise of multidrug resistance [79]. Hassan and colleagues reported the use of
vancomycin-coated magnetic nanoparticles as anti-bacterial agents [80]. The novel formulation was
tested against vancomycin resistant strains, exhibiting minimum inhibitory concentrations as low as
13–28 µg·mL 1 compared with 250–4000 µg·mL 1 for the free drug. Their nanoparticle formulation
rapidly permeated the cell membranes and presented a strategy for re-potentiating drugs [80].
Besides metallic nanoparticles, the use of polymers to deliver antibiotics has also been reported.
Turos and colleagues reported the development of a polymer-drug conjugate of a poly(acrylate) and an
N-thiolated beta-lactam drug [81]. The study documented that the nanoparticles formed were 40 nm
in diameter and that the preparations showed potent anti-bacterial properties when incubated with
methicillin-resistant S. aureus compared to the free drug. The authors noted the ease of tailoring of
these particles through modification of the acrylate linker that provided conjugation onto the drug
molecule [81]. Nguyen and colleagues have developed a sophisticated system in which they modified
gentamicin to contain a nitric oxide-releasing moiety [82] and the drug-moiety was then encapsulated
within a polymeric nanoparticle. The nanoparticle showed a synergistic antibacterial effect against
P. aeruginosa of up to 95% when the nitric oxide and drug were released simultaneously. In comparison,
administration of the drug alone or nitric oxide alone resulted in only a 20% reduction of bacterial
viability [82].
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5.6. Nanoparticle Biocompatibility
As most nanoparticulates are semi- or totally synthetic it is vital that the in vivo toxicity is as
low as possible, especially if the nanoparticle transports an antibiotic in a formulation that may
affect the normal mechanism and metabolism of the antibiotic. Furthermore, with the utilisation of
polymers combined with antibiotics, this may decrease the toxicity profile of the antibiotic which
will allow safer usage of these drugs. The mode of action of vancomycin (Figure 4) is via binding to
terminal D-Ala-D-Ala residues in precursors of the Gram-positive bacterial peptidoglycan cell wall
component [83], preventing formation of the peptide crosslinks which rigidify peptidoglycan (Figure 7).
In the case of vancomycin-resistant bacteria the D-Ala-D-Ala pendant is mutated into D-Ala-D-Lactate,
as is the case in VanA type resistance, or into D-Ala-D-Ser in VanB type resistance [84]. The genes
required for VanA type resistance are found on the transposable DNA fragment Tn1546, usually
found on a plasmid or within the bacterial genome [85]. The plasmid DNA is transferred between
bacterial cells by conjugation of the cells. The cells which acquire genetic information in this way will
now contain the required genes which code for VanA type resistance. Resistance to vancomycin is
predominantly observed in Enterococcus faecium where the presence of the requisite transposon Tn1546
(containing the vanA gene) or Tn1547 (containing the vanB gene) will give rise to the incorporation of
D-Ala-D-Lactate or D-Ala-D-Ser into the cell wall precursors, respectively, respectively [85]. Acquired
resistance to vancomycin in S. aureus (VRSA) due to incorporation of transposon Tn1546 into the
S. aureus genome is thankfully rare but may present a significant challenge [86]. Chakraborty and
colleagues showed that vancomycin conjugated to chitosan nanoparticles which were tagged with
folic acid showed anti-microbial activity against VRSA [87]. They explained the anti-bacterial action of
the folic acid by the polymer acting as the trojan horse which also allowed vancomycin to enter
bacteria more readily [87]. Moreover, using chitosan nanoparticles in the conjugated polymer
provided biocompatibility that reduced the toxicity profile of the polymer conjugate. Similarly,
poly(lactic-co-glycolic acid) (PLGA) nanoparticles, of diameters within a range 241–358 nm, entrapping
gentamycin were found to act against P. aeruginosa [88]. Here, the PLGA nanoparticles allowed
controlled release of gentamycin. Similar to chitosan, PLGA is clinically approved and is biocompatible
which facilitates usage in vivo [88].
Figure 7. Chemical structure of the peptidoglycan precursor in Gram-positive cells.
Similarly, PLGA nanoparticles have shown use as a drug carrier for anti-tuberculosis drugs.
Tuberculosis (TB) is a serious pathophysiological condition derived from the presence ofM. tuberculosis
bacteria, usually in the respiratory tract [89]. There are several antibiotics available to treat TB that
are reserved as first line therapies; however, resistance is also associated with their usage. Examples
of the drugs used in first line therapy are isoniazid and rifampicin (Figure 8). In terms of their
physiochemical properties, both drugs are lipophilic which affects their absorption when taken
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orally. Furthermore, there is difficulty in maintaining therapeutic plasma concentrations of the
drugs which usually requires several doses to be taken daily. Consequently, side effects occur more
frequently. Kalluru and colleagues highlighted the use of PLGA nanoparticles loaded with rifampicin
against M. tuberculosis [90]. As mentioned earlier, it is difficult to maintain a therapeutic plasma
concentration but Kalluru showed that with PLGA nanoparticles of diameter 228 nm loaded with
rifampicin therapeutic plasma concentrations were observed up to 12 days after injection in mice [90].
This indicates that the application of PLGA can greatly improve plasma concentrations of rifampicin
and its counterparts. This promising in vivo study could potentially be translated into human studies.
 
Figure 8. Chemical structures of (A) isoniazid and (B) rifampicin.
6. Conclusions and Future Perspectives
Anti-microbial resistance has changed the way antibiotics are used in today’s medicine, requiring
clinicians to focus increasingly on changing how antibiotics can be obtained and prescribed. There has
been little innovation to discover novel antibiotics that will achieve anti-bacterial action viamechanisms
which will be less prone to resistance. Nanotechnology is being exploited to solve complex issues in
biomedicine. There is tangible evidence for the effective use of nanotechnologies as anti-microbial
agents. Various strategies for the use of nanoparticles in antibiotic chemotherapy have been evaluated,
summarised in Figure 9.
 
Figure 9. Mechanisms by which nanoparticles can exert an antimicrobial effect: (A)Accumulation at
the cell wall surface; (B) Penetration of the cell, either through damaged cell wall or (C) endocytosis;
(D) Generation of reactive oxygen species externally or (E) internally; (F) Penetration of nanoparticle
and drug payload through damaged cell wall or (G) endocytosis; (H) Accumulation of nanoparticle
and drug payload on cell wall; (I) Release of drug payload externally or (J) internally; (K) Generation
of toxic metal ionic species.
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Thus, nanoparticle technologies have joined the armamentarium available in the combat against
anti-microbial resistance. Resistance to current antibiotics in bacteria could be ameliorated using
nanoparticle therapies as evidenced by existing studies. The growing evidence of nanoparticle
technologies showing anti-bacterial activity against an array of different pathogens shows a promising
future for the application of nanotechnology despite most of the evidence being obtained from
in vitro experiments. For nanotechnology to be at the forefront in the future development of modern
anti-microbial drugs further experiments will have to undertaken in vivo, especially involving human
subjects in clinical trial. Efficacy needs to be proven in humans since therapeutic doses may well be
accompanied by intolerable side effects that could inhibit the application of nanoparticles. This is
especially important for nanoparticles whose mode of action relies upon the production of ROS:
The prokaryotic cells of bacteria are not as complex as eukaryotic cells, which contain structures
and organelles that have vital roles in their biology. Ideally, the anti-bacterial action of species
which generate ROS would be specific to bacteria. However, eukaryotic cells can also be affected
by ROS which will have a detrimental impact on the host. Therefore, therapeutic considerations
are vital and empirical evidence is essential for nanoparticle therapies to be applicable in humans.
Nevertheless, the use of currently available antibiotics conjugated or associated with nanoparticles
brings an alternative dimension to antibiotic therapy: dual anti-bacterial modality using nanoparticles
can facilitate treatment and limit the development and impact of anti-microbial resistance. The size
and charged nature of nanoparticles can be exploited in the formation of antibiotic drug conjugates.
Furthermore, the physiochemical properties of nanoparticles give rise to additional options to deliver a
lethal effect to bacteria. In conclusion, there is tangible evidence for the application of nanotechnology
in anti-microbial therapies to combat the growing threat of resistance to antibiotics displayed by
pathogenic bacteria.
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